Medicus Pharma (NASDAQ:MDCX) Rating Lowered to “Strong Sell” at Wall Street Zen

Medicus Pharma (NASDAQ:MDCX) was downgraded by research analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a note issued to investors on Sunday, Wall Street Zen reports.

MDCX has been the topic of a number of other research reports. Weiss Ratings upgraded shares of Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Alliance Global Partners restated a “buy” rating on shares of Medicus Pharma in a research report on Monday, September 14th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $450.00.

Medicus Pharma Price Performance

Shares of Medicus Pharma stock opened at $1.89 on Friday. Medicus Pharma has a 1 year low of $1.70 and a 1 year high of $127.50. The firm’s 50-day moving average is $5.92 and its 200 day moving average is $21.39. The stock has a market cap of $2.38 million, a price-to-earnings ratio of -0.02 and a beta of 0.80.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings data on Friday, November 6th. The company reported ($11.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.91) by ($5.73). On average, equities analysts expect that Medicus Pharma will post -36.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MDCX. Interchange Capital Partners LLC increased its holdings in Medicus Pharma by 33.9% in the 3rd quarter. Interchange Capital Partners LLC now owns 2,124,910 shares of the company’s stock worth $343,000 after acquiring an additional 538,039 shares in the last quarter. Sterling Investment Advisors Ltd. purchased a new stake in shares of Medicus Pharma in the second quarter worth $45,000. Finally, Private Advisor Group LLC increased its stake in shares of Medicus Pharma by 36.8% in the first quarter. Private Advisor Group LLC now owns 240,055 shares of the company’s stock worth $110,000 after purchasing an additional 64,560 shares in the last quarter.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.